Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis

Current Opinion in Lipidology

Volumn 9, Issue 5, 1998, Pages 413-423

  George, Sarah Jane ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; METALLOPROTEINASE; SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANGIOGENESIS; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL DEATH; CELL GROWTH; CELL INFILTRATION; INFLAMMATION; INFLAMMATORY CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW; RUPTURE;

ARTERIOSCLEROSIS; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; METALLOENDOPEPTIDASES; MUSCLE DEVELOPMENT; MUSCLE, SMOOTH, VASCULAR;

EID: 0031788693     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199810000-00005     Document Type: Review

References (134)

1. Ross R. Atherosclerosis - a defence mechanism gone awry. Am J Pathol 1993; 143:987-1002.
2. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53:363-373.
3. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94:2493-2503.
4. Nikkari ST, Obrien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, Clowes AW. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995; 92:1393-1398.
5. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77:863-868.
6. Murphy G, Docherty AJP, Hembry RM, Reynolds JJ. Metalloproteinases and tissue damage. Br J Rheumatol 1991; 30:25-31.
7. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodelling. TIG 1990; 6:121-125.
8. Galis ZS, Muszynski M, Sukhova GK, Simon-Morissey E, Unemori EN, Lark MW, et al. Cytokine-stimulated human vascular smooth muscle synthesise a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75:181-189.
9. Fabunmi RP, Baker AH, Murray EJ, Booth RFG, Newby AC. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells. Biochem J 1996; 315:335-342.
10. Lee E, Grodzinsky AJ, Libby P, Clinton SK, Lark MW, Lee RT. Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture. Arterioscler Thromb Vasc Biol 1995; 15:2284-2289.
11. Shapiro SD, Campbell EJ, Kobayashi DK, Welgus HG. Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-γ. J Clin Invest 1990; 86:1204-1210.
12. Xie B, Dong Z, Fidler IJ. Regulatory mechanisms for the expression of type IV collagenases/gelatinases in murine macrophages. J Immunol 1994; 152:3637-3644.
13. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96:2304-2310.
14. Sasaguri T, Arima N, Tanimoto A, Shimajiri S, Hamada T, Sasaguri Y. A role for interleukin 4 in production of matrix metalloproteinase 1 by human aortic smooth muscle cells. Atherosclerosis 1998; 138:247-253. This study suggests that interleukin-4 and possibly other cytokines released from inflammatory cells may play a role in inhibition or regression of atherosclerotic plaques.
15. Satoh T, Sugama K, Matsuo A, Kato S, Ito S, Hatanaka M, Sasaguri Y. Histamine as an activator of cell growth and extracellular matrix reconstruction for human vascular smooth muscle cells. Atherosclerosis 1994; 110:53-61.
16. Yanagi H, Sasaguri Y, Sugama K, Morimatsu M, Nagase H. Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis 1992; 91:207-216.
17. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of the basic fibroblast growth factor in vascular lesion formation. Circ Res 1991; 68:106-113.
18. Pickering JG, Ford CM, Tang B, Chow LH. Co-ordinated effects of fibroblast growth factor-2 on expression of fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells - evidence for repressed collagen production and activated degradative capacity. Arterioscler Thromb Vasc Biol 1997; 17:475-482. This work clearly demonstrates that fibroblast growth factor-2 stimulates collagen degradation by inducing MMP-1 and reducing TIMP-2 production as well as inhibiting collagen synthesis. The authors suggest that growth factors may be critical in coordinating the balance between ECM synthesis and degradation.
19. Lacraz S, Isler P, Vey E, Welgus HG, Dayer J-M. Direct contact between T-lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem 1994; 269:22027-22033.
20. Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996; 156:3952-3960.
21. Mach F, Schönbeck U, Bonnefoy J-Y, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40. Induction of collagenase, stromelysin, and tissue factor. Circulation 1997; 96:396-399. In this excellent study, it is demonstrated for the first time that cell-cell contact between activated T lymphocytes and macrophages though CD40 ligation induces MMP-1 and -3 expression.
22. Mach F, Schönbeck U, Sukhova GK, Bourcier T, Bonnefoy J-Y, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signalling in atherosclerosis. Proc Natl Acad Sci U S A 1997; 94:1931-1936.
23. Schönbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy J-Y, Fabunmi RP, et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by lymphocytes. A role for CD40 signalling in plaque rupture? Circ Res 1997; 81:448-454. This work illustrates that CD40 ligand expressed on T cells promotes expression of MMP-1, MMP-3 and MMP-9 in vascular SMC, adding further strength to the hypothesis that CD40 ligation plays a pivotal role in MMP induction in atherosclerotic plaque development.
24. Mach F, Schönbeck U, Libby P. CD40 signalling in vascular cells: a key role in atherosclerosis? Atherosclerosis 1998; 137 (Suppl.):S89-S95. This review summarizes the proposal that CD40 ligation orchestrates immune-modulated destabilization of human atherosclerotic plaques.
25. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378:151-160.
26. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle ot regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 1990; 87:5578-5582.
27. Sato H, Takin T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370:61-65.
28. Takino T, Sato H, Yamamoto E, Seiki M. Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain. Gene 1995; 155:293-298.
29. Will H, Hinzmann B. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem 1995; 231:602-608.
30. Takino T, Sato H, Shinagawa A, Seiki M. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library - MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem 1995; 270:23013-23020.
31. Puente XS, Pendas AM, Llano E, Velasco G, Lopez-Otin C. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 1996; 56:944-949.
32. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell-surface activation of 72 kDa type IV collagenase -isolation of the activated form of membrane metalloprotease. J Biol Chem 1995, 270:5331-5339.
33. Pei DQ, Weiss SJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 1996; 271:9135-9140.
34. Matsumoto S, Katoh M, Saito S, Watanabe T, Masuho Y. Identification of soluble type of membrane-type matrix metalloproteinase-3 formed by alternatively spliced mRNA. Biochim Biophys Acta 1997; 1354:159-170. MT3-MMP, which plays a role in ECM turnover by activating proMMP-2, may also act directly on ECM macromolecules as a soluble MT3-MMP formed by alternative mRNA splicing.
35. Imai K, Ohuchi E, Aoki T, Nomura H, Fuji Y, Sato H, et al. Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases2. Cancer Res 1996; 56:2707-2710.
36. Lichte A, Kolkenbrock H, Tschesche H. The recombinant catalytic domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) induces activation of progelatinase A and progelatinase A complexed with TIMP-2. FEBS Lett 1996; 397:277-282.
37. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995; 375:244-247.
38. Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 1996; 393:101-104.
39. Cao JA, Rehemtulla A, Bahou W, Zucker S. Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain. J Biol Chem 1996; 271:30174-30180.
40. Greene J, Wang MS, Liu YLE, Raymond LA, Rosen C, Shi YNE. Molecular cloning and characterisation of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271:30375-30380.
41. Nagase H, Itoh Y, Binner S. Interaction of α2-macroglobulin with matrix metalloproteinases and its use for identification of their active forms. In: Greenwald RA, Golub LM, editors. Inhibition of matrix metalloproteinases: therapeutic potential. New York: NY Acad Sci; 1994. pp. 294-302.
42. Gerrity RG. The role of the monocyte in atherogenesis. II. Migration of foam cells from atherosclerotic lesions. Am J Pathol 1981; 103:191-200.
43. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 1993; 92:945-951.
44. Romanic AM, Madri JA. The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J Cell Biol 1994; 125:1165-1178.
45. Madri JA, Graesser D, Haas T. The roles of adhesion molecules and proteinases in lymphocyte transendothelial migration. Biochem Cell Biol 1996; 74:749-757.
46. Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr, Richardson M, et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Arterioscler Thromb 1992; 12:120-134.
47. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92:1355-1374.
48. Wesley RB, Meng X, Godin D, Galis ZS. Extracellular matrix modulates macrophage functions characteristic to atheroma. Collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler Thromb Vasc Biol 1998; 18:432-440. This excellent study shows that interaction with vascular matrix, especially collagen type I, induces MMP-9 expression and may play an important role monocyte differentiation into macrophages and monocyte migration.
49. Khan KMF, Falcone DJ. Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression. J Biol Chem 1997; 272:8270-8275.
50. Gudewicz PW, Frewin MB, Heinel LA, Minnear FL. Priming of human monocyte Superoxide production and arachidonic acid metabolism by adherence to collagen- and basement membrane-coated surfaces. J Leukoc Biol 1994; 55:423-429.
51. Pacifici R, Basilico C, Roman J, Zutter MM, Santoro SA, McCracken R. Collagen-induced release of interleukin 1 from human blood mononuclear cells: potentiation by fibronectin binding to the alpha5beta1 integrin. J Clin Invest 1992; 89:61-67.
52. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro - implications for atherosclerotic plaque stability. J Clin Invest 1996; 98:2572-2579.
53. Jones PA, Werb Z. Degradation of connective tissue matrices by macrophages. II. Influence of composition on proteolysis of glycoproteins, elastin, and collagen by macrophages in culture. J Exp Med 1980; 152:1527-1536.
54. Aggeler J, Frisch SM, Werb Z. Changes in cell shape correlated with collagenase gene expression in rabbit synovial fibroblasts. J Cell Biol 1984; 98:1662-1671.
55. Campbell GR, Campbell JH. The phenotypes of smooth muscle expressed in human atheroma. Ann NY Acad Sci 1990; 598:143-158.
56. Campbell JH, Kalevitch SG, Rennick RE, Campbell GR. Extracellular matrix-smooth muscle phenotype modulation by macrophages. Ann NY Acad Sci 1990; 598:159-166.
57. Southgate KM, Davies M, Booth RFG, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J 1992; 288:93-99.
58. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994; 75:539-545.
59. Zempo N, Kenagy RD, Au T, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid. J Vasc Surg 1994; 20:209-217.
60. Webb KE, Henney AM, Anglin S, Humphries SE, McEwan JR. Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury. Arterioscler Thromb Vasc Biol 1997; 17:1837-1844. Expression of members of the MMP family (MMP-2, MMP-9, MMP-3 and TIMP-1) in the rat carotid artery is temporally regulated after balloon injury.
61. Forough R, Hasenstab D, Zempo N, Langley K, De Clerck Y, Clowes A. Induction of tissue inhibitor of metalloproteinase-2 in injured rat artery. In: Greenwald RA, Golub LM, editors. Inhibition of matrix metalloproteinases: therapeutic potential. New York: NY Acad Sci; 1994. pp. 384-388.
62. Hasenstab D, Forough R, Clowes AW. Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats. Circ Res 1997; 8:490-496. This study demonstrates that TIMP-2 is also temporally regulated after balloon injury of the rat carotid and illustrates the complexity of the involvement of the MMP family during periods of SMC migration and proliferation.
63. Wang H, Kaiser JA. Expression of membrane-type matrix metalloproteinase in rabbit neointimal tissue and its correlation with matrix-metalloproteinase-2 activation. J Vasc Res 1998; 35:45-54. The authors note a close temporal expression pattern between MT1-MMP and active MMP-2, which suggests its importance in MMP-2 activation in rabbit arteries after injury.
64. Jenkins GM, Crow MT, Bilato C, Gluzband Y, Ryu W-S, Li Z, et al. Increased expression of membrane-type matrix metalloproteinase and preferential localisation of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries. Circulation 1998; 97:82-90. This study demonstrates that MT1-MMP and active MMP-2 are colocated, which suggests that MT1-MMP is involved in the activation of MMP-2 after balloon injury of the rat carotid injury.
65. Galis ZS, Kranzhöfer R, Fenton JW, Libby P. Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17:483-489. The results of this study demonstrate that in-vitro thrombin activates MMP-2, suggesting that it may play a role in plaque stability.
66. Bar-Shavit R, Benezra M, Sabbah V, Bode W, Vlodavsky I. Thrombin as a multifunctional protein: induction of cell adhesion and proliferation. Am J Respir Cell Mol Biol 1992; 6:123-130.
67. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 1996; 16:28-33.
68. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996; 78:38-43.
69. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998; 101:1478-1487. In addition to demonstrating that overexpression of TIMP-1, TIMP-2 and TIMP-3 using replication deficient adenoviruses reduces SMC migration, this study shows that overexpression of TIMP-3 induces apoptosis in SMC. SMC apoptosis may be involved in plaque instability by weakening the lesion at the shoulder regions or within the fibrous cap.
70. Forough R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari ST, Clowes AW. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res 1996; 79.812-820.
71. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits SMC migration and neointima formation in human saphenous vein. Human Gene Therapy 1998; 9:867-877. A demonstration that overexpression of TIMP-1 using replication deficient adenoviruses inhibits neointima formation in human saphenous vein organ cultures by reducing SMC migration.
72. Barger AC, Beeuwkes R, Lainey LL, Silverman KV. Hypothesis: vasa vasorum and neovascularisation of human coronary arteries. Possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984; 310:175.
73. Zhang Y, Cliff WJ, Schoefl GI, Higgins G. Immunohistochemical study of intimai microvessels in coronary atherosclerosis. Am J Pathol 1993; 143:164-172.
74. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. Hum Pathol 1995; 26:450-456.
75. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. II Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem 1986; 261:2814-2818.
76. Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN, et al. Type IV collagenases(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993; 156:235-246.
77. Johnson MD, Kim H-RC, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994; 160:194-202.
78. Galardy RE, Grobelny D, Foellmer HG, Fernandez LA. Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2-(hydrox-amidocarbonymethyl)-4-methylpentanoyl)]-L-trytophan methylamide. Cancer Res 1994; 54:4715-4718.
79. Brooks PC, Stromblad S, Sanders LC, Vonschalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localisation of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85:683-693.
80. McMillan WD, Patterson BK, Keen RR, Shively VP, Cipollone M, Pearce WH. In situ localisation and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. Arterioscler Thromb Vasc Biol 1995; 15:1139-1144.
81. Sunderkötter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994; 55:410-422.
82. Zucker S, Conner C, DiMassmo BL, Ende H, Drews M, Seiki M, Bahou WF. Thrombin induces the activation of progelatinases A in vascular endothelial cells. Physiologic regulation of angiogenesis. J Biol Chem 1995; 270:23730-23738.
83. Duhamel-Clérin E, Orvain C, Lanza F, Cazenave J-P, Klein-Soyer C. Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3 in human endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17:1931-1938. It was observed that thrombin causes activation of MMP-2 and increased production of MMP-1 and MMP-3 through G-protein coupled thrombin receptor signalling in endothelial cells in vitro, suggesting that thrombin may be involved in tissue remodelling and angiogenesis.
84. Peracchia F, Tamburro A, Prontera C, Mariani B, Rotilio D. cAMP involvement in the expression of MMP-2 and MT-MMP1 metalloproteinases in human endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17:3185-3190. This study demonstrates that elevation of cAMP by forskolin inhibits MMP-2 activation in endothelial cells in vitro by decreasing the expression of MT-MMP-1.
85. Falk E. Why do plaques rupture? Circulation 1992; 86:30-42.
86. Shah PK. Pathophysiology of plaque rupture and the concept of plaque stabilisation. Cardiol Clin 1996; 14:17-29.
87. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterised by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89:36-44.
88. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation 1993; 87:1179-1187.
89. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2:941-944.
90. Libby P. Lesion versus lumen. Nature Med 1995; 1:17-18.
91. Lendon CL, Davies MJ, Born GVR, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis 1991; 87:87-90.
92. Shah PK, Falk E, Badimon JJ, Fernandezortiz A, Mailhac A, Villareallevy G, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92:1565-1569.
93. Galis ZS, Sukhova GK, Kranzhöfer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A 1995; 92:402-406.
94. Shapiro SD, Campbell EJ, Senior RM, Welgus HG. Proteinases secreted by human mononuclear phagocytes. J Rheumatol 1991; 18 (Suppl. 27):95-98.
95. Nikkari ST, Geary RL, Hatsukami T, Ferguson M, Forough R, Allpers CE, Clowes AW. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinase-1 in restenosis after carotid endarterectomy. Am J Pathol 1996; 148:777-783.
96. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S. Localisation of stromelysin gene expression in atherosclerotic plaques by in situ hybridisation. Proc Natl Acad Sci U S A 1991; 88:8154-8158.
97. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91:2125-2131.
98. Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localises to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A 1996; 93:9748-9753.
99. Li Z, Li L, Zielke R, Cheng L, Xiao R, Crow MT, et al. Increased expression of 72-kD type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 1996; 148:121-128.
100. Johnson JL, Jackson CL, Angelini GD, George SJ. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Heart 1998; 79 (Suppl. 1):35. In this study it is demonstrated that the release of the neutral proteases, chymase and tryptase, causes the activation of MMPs in atherosclerotic plaques. This is the first direct illustration of a mechanism of MMP activation in plaques.
101. Frears ER, Zhang Z, Blake DR, O'Connell JP, Winyard PG. Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett 1996; 381:21-34.
102. Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis -implications for plaque rupture. Arterioscler Thromb Vasc Biol 1996; 16:1070-1073.
103. Lijnen HR, Ugwu F, Bini A, Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 1998; 37:4699-4702. The results presented here show that MMP-3 can cleave plasminogen and generate angiostatin-like fragments that may regulate angiogenesis.
104. Patterson BC, Sang QXA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B type IV collagenase (MMP-9). J Biol Chem 1997; 272:28823-28825. This study demonstrates that MMP-9 and MMP-7 can also cleave plasminogen yielding angiostatin molecules which may be involved in regulating angiogenesis.
105. Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997; 88:801-810.
106. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem 1994; 269:25742-25746.
107. Chandler S, Cossins J, Lury J, Wells G. Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-α fusion protein. Biochem Biophys Res Commun 1996; 228:421-429.
108. Blobel CP. Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNFα and notch. Cell 1997; 90:589-592. This concise review summarizes the potential roles of the MDC family of proteases in protein processing.
109. Herren B, Raines EW, Ross R. Expression of a disintegrin-like protein in cultured human vascular cells and in vivo. FASEB J 1997; 11:173-180.
110. Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 1997; 11:355-364.
111. Wang X, Douglas SA, Louden C, Vickery-Clark LM, Feuerstein GZ, Ohlstein EH. Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circ Res 1996; 78:322-328.
112. Minamino T, Kurihara H, Takahashi M, Shimada K, Maemura K, Oda H, et al. Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis. Circulation 1997; 95:221-230.
113. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994; 370:218-220.
114. Müllberg J, Durie FH, Ottens-Evans C, Alderson MR, Rose-John S, Cosman D, et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995; 155:5198-5205.
115. McGeehan GM, Becherer JD, Bast RC Jr, Boyer CM, Champion B, Connolly KM, et al. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994; 370:558-561.
116. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, et al. Processing of tumour necrosis factor-a precursor by metalloproteinases. Nature 1994; 370:555-557.
117. Moss ML, Jin SLC, Milla ME, Burkhart W, Carter HL, Chen W-J, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385:733-736.
118. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385:729-733.
119. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA. Ware CF. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995; 181:1205-1210.
120. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S. et al. Metalloproteinase-mediated release of human fas ligand. J Exp Med 1995; 182:1777-1783.
121. Preece G, Murphy G, Ager A. Metalloproteinase-mediated regulation of L-selectin levels on leukocytes. J Biol Chem 1996; 271:11634-11640.
122. Bennett TA, Lynam EB, Sklar LA, Rogelj S. Hydroxamate-based metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from leukocytes: functional consequences for neutrophil aggregation. J Immunol 1996; 156:3093-3097.
123. Arribas J, Goodly L, Vollmer P, Kishikmoto TK, Rose-John S, Massague J. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 1996; 271:11376-11382.
124. Willmroth F, Peter HH, Conca W. A matrix metalloproteinase gene expresses in human T lymphocytes is identical with collagenase 3 from breast carcinomas. Immunobiology 1998; 198:375-384.
125. Bennett MR, Evan GI, Newby AC. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotide analogues and induces apoptosis. Circ Res 1994; 74:525-536.
126. Geng Y-J, Libby P. Evidence for apoptosis in advanced human atheroma. Colocalisation with interleukin-1b-converting enzyme. Am J Pathol 1995; 147:251-266.
127. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992; 298:29-32.
128. Stetler-Stevenson WG, Bersch N, Golde DW. Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett 1992; 296:231-234.
129. Yamashita K, Suzuki M, Iwata H, Koike T, Hamaguchi M, Shinagawa A, et al. Tyrosine phosphorylation is crucial for growth signalling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). FEBS Lett 1996; 396:103-107.
130. Yang T-T, Hawkes SP. Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc Natl Acad Sci U S A 1992; 89:10676-10680.
131. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinase-2 (TIMP-2). J Cell Sci 1994; 107:2373-2379.
132. Bertaux B, Hornebeck W, Eisen AZ, Dubertret L. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 1991; 97:679-685.
133. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73:209-215.
134. Ye S, Humphries S, Henney A. Matrix metalloproteinases: implication in vascular matrix remodelling during atherogenesis. Clin Sci 1998; 94:103-110. This review summarizes this groups findings concerning a genetic variation in the human stromelysin promoter. The authors found that the 6A allele has a lower promoter reactivity and is associated with the progression of atherosclerosis. Therefore, they suggest that this allele favours matrix deposition and lesion development.